CBD Co. Execs Hit With Derivative Suit Over Patent Rejection
Executives from CBD company CV Sciences are facing a shareholder derivative suit over claims they hid the fact its application for a patent on a CBD and nicotine product was denied,...To view the full article, register now.
Already a subscriber? Click here to view full article